» Articles » PMID: 35370740

A Critical Review of Zebrafish Models of Parkinson's Disease

Overview
Journal Front Pharmacol
Date 2022 Apr 4
PMID 35370740
Authors
Affiliations
Soon will be listed here.
Abstract

A wide variety of human diseases have been modelled in zebrafish, including various types of cancer, cardiovascular diseases and neurodegenerative diseases like Alzheimer's and Parkinson's. Recent reviews have summarized the currently available zebrafish models of Parkinson's Disease, which include gene-based, chemically induced and chemogenetic ablation models. The present review updates the literature, critically evaluates each of the available models of Parkinson's Disease in zebrafish and compares them with similar models in invertebrates and mammals to determine their advantages and disadvantages. We examine gene-based models, including ones linked to Early-Onset Parkinson's Disease: , and ; but we also examine which is linked to Late-Onset Parkinson's Disease. We evaluate chemically induced models like MPTP, 6-OHDA, rotenone and paraquat, as well as chemogenetic ablation models like metronidazole-nitroreductase. The article also reviews the unique advantages of zebrafish, including the abundance of behavioural assays available to researchers and the efficiency of high-throughput screens. This offers a rare opportunity for assessing the potential therapeutic efficacy of pharmacological interventions. Zebrafish also are very amenable to genetic manipulation using a wide variety of techniques, which can be combined with an array of advanced microscopic imaging methods to enable visualization of cells and tissue. Taken together, these factors place zebrafish on the forefront of research as a versatile model for investigating disease states. The end goal of this review is to determine the benefits of using zebrafish in comparison to utilising other animals and to consider the limitations of zebrafish for investigating human disease.

Citing Articles

Motor and Non-Motor Effects of Acute MPTP in Adult Zebrafish: Insights into Parkinson's Disease.

Tagkalidou N, Stevanovic M, Romero-Alfano I, Elizalde-Velazquez G, Herrera-Vazquez S, Prats E Int J Mol Sci. 2025; 26(4).

PMID: 40004138 PMC: 11855887. DOI: 10.3390/ijms26041674.


Zebrafish as a Suitable Model for Utilizing the Bioactivity of Coumarins and Coumarin-Based Compounds.

Lachowicz-Radulska J, Widelski J, Nowaczynski F, Serefko A, Sobczynski J, Ludwiczuk A Int J Mol Sci. 2025; 26(4).

PMID: 40003910 PMC: 11855297. DOI: 10.3390/ijms26041444.


Modeling of Parkinson's Disease in Different Models.

Subhan I, Siddique Y CNS Neurol Disord Drug Targets. 2024; 24(2):102-114.

PMID: 39354776 DOI: 10.2174/0118715273326866240922193029.


A review of MPTP-induced parkinsonism in adult zebrafish to explore pharmacological interventions for human Parkinson's disease.

Bagwell E, Larsen J Front Neurosci. 2024; 18:1451845.

PMID: 39170675 PMC: 11335677. DOI: 10.3389/fnins.2024.1451845.


Zebrafish: unraveling genetic complexity through duplicated genes.

Tasnim M, Wahlquist P, Hill J Dev Genes Evol. 2024; 234(2):99-116.

PMID: 39079985 PMC: 11612004. DOI: 10.1007/s00427-024-00720-6.


References
1.
Cuervo A, Stefanis L, Fredenburg R, Lansbury P, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004; 305(5688):1292-5. DOI: 10.1126/science.1101738. View

2.
Bhat A, Dar K, Anees S, Zargar M, Masood A, Sofi M . Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed Pharmacother. 2015; 74:101-10. DOI: 10.1016/j.biopha.2015.07.025. View

3.
Godoy R, Noble S, Yoon K, Anisman H, Ekker M . Chemogenetic ablation of dopaminergic neurons leads to transient locomotor impairments in zebrafish larvae. J Neurochem. 2015; 135(2):249-60. DOI: 10.1111/jnc.13214. View

4.
Sallinen V, Torkko V, Sundvik M, Reenila I, Khrustalyov D, Kaslin J . MPTP and MPP+ target specific aminergic cell populations in larval zebrafish. J Neurochem. 2008; 108(3):719-31. DOI: 10.1111/j.1471-4159.2008.05793.x. View

5.
Braak H, Braak E . Pathoanatomy of Parkinson's disease. J Neurol. 2000; 247 Suppl 2:II3-10. DOI: 10.1007/PL00007758. View